
^ "Priligy is used to Treat Premature Ejaculation". ^ a b c "Australian Public Assessment Report for Dapoxetine" (PDF). "Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation". "Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation". ^ "Furiex Pharma gets rights to Priligy, some of which it sells on to Menarini". "New agents in the priligy 15 mg treatment of premature ejaculation". "Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials". "Dapoxetine has long-term efficacy in the treatment of premature ejaculation". "AUA guideline on the pharmacologic management of premature ejaculation". "Dapoxetine: An Innovative Approach in the Therapeutic Management In Animal Model of Depression". "Antistress and antidepressant properties of dapoxetine and vortioxetine". "Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries". "Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: A 2-Year Prospective Observational Study".
It has also been approved in France, Russia, Malaysia, Philippines, Argentina, and Uruguay. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Archived from the original on 2023-08-03. "Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors". "Dapoxetine: a new option in the medical management of premature ejaculation". "Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction". "Dapoxetine-A Novel Drug for Premature Ejaculation".
"Dapoxetine for the treatment of premature ejaculation: Lack of interaction with ethanol". "Monoaminergic transporter binding and inhibition profile of dapoxetine, a medication for the treatment of premature ejaculation". "Physiology of ejaculation: emphasis on serotonergic control". "Supraspinal site of action for the inhibition of ejaculatory reflex by dapoxetine".
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Priligy Generic Dapoxetine | 60mg | 180 + 10 Pills | 494.76€ 471.20€ | |
| Priligy Generic Dapoxetine | 60mg | 30 + 6 Pills | 106.65€ 101.57€ | |
| Levitra Generic | 20mg | 360 + 10 Pills | 458.44€ 436.61€ | |
| Viagra Generic | 50mg | 270 + 8 Pills | 198.48€ 189.03€ | |
| Priligy Generic Dapoxetine | 60mg | 90 + 10 Pills | 265.64€ 252.99€ | |
| Viagra Generic | 50mg | 360 + 10 Pills | 225.33€ 214.60€ | |
| Priligy Generic Dapoxetine | 60mg | 60 + 8 Pills | 183.06€ 174.34€ | |
| Levitra Professional | 20mg | 30 Pills | 119.12€ 113.45€ | |
| Priligy Generic Dapoxetine | 60mg | 20 + 4 Pills | 77.31€ 73.63€ | |
| Priligy Generic Dapoxetine | 60mg | 10 Pills | 47.63€ 45.36€ | |
| Priligy Generic Dapoxetine | 60mg | 120 + 10 Pills | 341.26€ 325.01€ |
"Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials". ^ "Dapoxetine: a guide to its use in premature ejaculation". "Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers".
| Area of Research | Focus | Potential Outcomes |
|---|---|---|
| New formulations | Extended-release versions | Longer efficacy, fewer doses |
| Combination therapy | Priligy + other PDE5 inhibitors | Improved sexual performance |
| Pharmacogenomics | Genetic factors influencing response | Personalized dosing guidelines |
| Safety profile studies | Long-term safety and rare side effects | Broader approval, safer use |
"Cardiovascular safety profile of dapoxetine during the premarketing evaluation". "Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports". "Selective serotonin reuptake inhibitor discontinuation syndrome: a review". "Emerging treatments for premature ejaculation: focus on dapoxetine". "Dapoxetine: a novel treatment for premature ejaculation". "Stereoselective synthesis of (S)-dapoxetine starting from trans-cinnamyl alcohol". "Medical Non-Endocrine-Targeted Therapies: Ejaculatory Dysfunction and Immunotherapy". Diseases Companies Products Productz Mechanisms of Action Sites Priligy (dapoxetine) / AbbVie Welcome, Profile Billing Logout 6 Diseases 18 Trials 18 Trials 208 News 1 2 3 4 » Priligy (dapoxetine) / AbbVie Journal: Combined chiral-achiral supercritical fluid chromatography method for the impurity analysis of dapoxetine reveals insights in entropy-driven retention and acid-modulated selectivity.
| Aspect | Description | Approved Uses |
|---|---|---|
| Active Ingredient | Dapoxetine | Premature Ejaculation |
| Drug Class | Selective Serotonin Reuptake Inhibitor (SSRI) | Sexual Dysfunction Treatment |
| Manufacturer | Johnson & Johnson | Approved Countries |
| Typical Dosage | 30 mg or 60 mg | Usage Guidelines |
(Pubmed Central) - Dec 4, 2025 The neutral complexes impact retention depending on the amine substitution pattern and may suppress polar and enhance hydrophobic interactions.
These results underscore the potential application of combined additive systems to enhance SFC applications in the field of ionizable analytes.
[30][31] No study on the effects of SSRIs in men with PE has been done. McMahon's study in 2012 showed that dapoxetine has no effect on mood and is not associated with anxiety or suicidality. The incidence of antidepressant discontinuation syndrome symptoms in men using dapoxetine to treat PE has been described by reviewers as low or no different from the incidence of such symptoms in men withdrawn from placebo treatment. [33][34] The lack of chronic serotonergic stimulation with on-demand dapoxetine minimizes the potentiation action of serotonin at synaptic cleft, thus decreasing the risk of discontinuation symptoms. Currently, very few methods are used to synthesize (S)-dapoxetine.
This novel approach consists of only six steps in which three main steps are shown above. The initial reactant is trans-cinnamyl alcohol, which is commercially available. Sharpless asymmetric epoxidation and Mitsunobu reaction have been used to produce expected (S)-dapoxetine. This method is considered a good choice compared to the known methods due to high yield and easily obtainable reactants. Dapoxetine was created by Eli Lilly and in phase I clinical trial as an antidepressant. Priligy (dapoxetine) / AbbVie Retrospective data, Journal: Dapoxetine combined with non-pharmacological approaches for lifelong premature ejaculation.
It never worked out well as a medication for the treatment of depression, though, and was shelved for a while before subsequently developed to treat PE. In December 2003, Eli Lilly sold the patent for dapoxetine to Pharmaceutical Product Development (PPD) for US$65 million. Eli Lilly may also receive royalties payment from PPD if the sale exceeds a certain amount. Research into the effectiveness of dapoxetine was revisited in 2020. ALZA is the current owner of dapoxetine, but PPD will receive milestone payments and drug royalties from ALZA.
If approved, dapoxetine will be marketed in the US by Ortho McNeil pharmaceutical, Inc. Ortho McNeil and Janssen-Ortho Inc, or Janssen-Cilag are all units of Johnson & Johnson. As at 2005, dapoxetine was in phase III clinical trials, pending review by the FDA. Dapoxetine has been marketed and approved in more than 50 countries. [39] Dapoxetine has been approved in Italy, Spain, Mexico, South Korea, and New Zealand in 2009 and 2010; marketed in Sweden, Austria, Germany, Finland, Spain, Portugal, and Italy. (Pubmed Central) - Nov 12, 2025 Combination therapy increases IELT, reduces PEDT scores, and improves PEP scores. These findings suggest that combination therapy is more effective than dapoxetine monotherapy in improving functional outcomes and self-perception in patients with LPE, supported by moderate certainty of evidence.
These effects cause an increase in pudendal motoneuron reflex discharge (PMRD) latency, though whether dapoxetine acts directly on LPGi or on the descending pathway in which LPGi located is unclear. Dapoxetine is a white, powdery, water-insoluble substance. Taken one to three hours before sexual activity, it is rapidly absorbed in the body. Its maximum plasma concentration (Cmax) is reached one to two hours after oral administration. The Cmax and AUC (area under the plasma vs.
time curve) is dose dependent. The Cmax and Tm (time needed to obtain the maximum plasma concentration) after single doses of dapoxetine 30 mg and 60 mg are 297 and 498 ng/ml at 1.01 and 1.27 hours, respectively. A high-fat meal does reduce the Cmax slightly, but it is insignificant. It can be taken with or without food. Dapoxetine is absorbed and distributed rapidly in the body. , Priligy (dapoxetine) / AbbVie Journal: Enantiodivergent Rh-Catalyzed Reductive Hydroformylation of Alkenyl Boronic Esters. (Pubmed Central) - Nov 11, 2025 DFT calculation has revealed the origin of enantiodivergence of Rh-catalyzed reductive AHF of alkenyl boronic esters with Ph-BPE as the chiral ligand.
The mean steady-state volume is 162 L. Its initial half-life is 1.31 hours (30 mg dose) and 1.42 hours (60 mg dose), and its terminal half life is 18.7 hours (30 mg dose) and 21.9 hours (60 mg dose). Dapoxetine is metabolized extensively in the liver and kidney by multiple enzymes such as CYP2D6, CYP3A4, and flavin monooxygenase 1. The major product at the end of the metabolic pathway is circulating dapoxetine N-oxide, which is a weak SSRI and contributes no clinical effect. The metabolites of dapoxetine are eliminated rapidly in the urine with a terminal half-life of 18.7 and 21.9 hours for a single dose of 30 mg and 60 mg, respectively.
The cardiovascular safety profile of dapoxetine has been studied extensively during the drug development. Phase I trials showed that dapoxetine had neither clinically significant electrocardiographic effects nor delayed repolarization effects, with dosing up to four-fold greater than the maximum recommended dosage, which is 60 mg. Phase III studies in men with PE showed a safety and well tolerated profile of dapoxetine with dosing of 30 and 60 mg. No cardiovascular adverse had been found. Studies of SSRIs in patients with major psychiatric disorders prove that SSRIs are potentially associated with certain neurocognitive adverse effects such as anxiety, akathisia, hypomania, changes in mood, or suicidal thought. The transformation is promised to provide great synthetic potential in both academia and industry. Priligy (dapoxetine) / AbbVie Preclinical, Journal: Frequency-Dependent Effects of Repetitive Transcranial Magnetic Stimulation on Sexual Behavior Parameters in Premature Ejaculation Rodent Models. (Pubmed Central) - Nov 8, 2025 rTMS exhibited frequency-dependent therapeutic efficacy in rapid ejaculation rat models, with high-frequency protocols demonstrating superior benefits compared with low-frequency interventions. These effects are mediated through activation of the BDNF-TrkB pathway and enhanced serotonergic signaling, suggesting high-frequency rTMS as a promising non-pharmacological therapy for PE. Priligy (dapoxetine) / AbbVie New trial: Study on the efficacy and safety of rTMS combined with dapoxetine hydrochloride in the treatment of premature ejaculation (EUDRACT) - Oct 30, 2025 P=N/A , N=90, Not yet recruiting, Sponsor: The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University Priligy (dapoxetine) / AbbVie Journal: The Inaugural Pre-Treatment Nomogram to Assess the Eight-Week Efficacy of Dapoxetine: A Prospective Multi-Center Study.